Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4270-4276

  Colombo, Renzo ^a   Da Pozzo, Luigi Filippo ^a   Salonia, Andrea ^a   Rigatti, Patrizio ^a   Leib, Zvi ^a   Baniel, Jack ^a   Caldarera, Emanuele ^a   Pavone Macaluso, Michele ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MICROWAVE IRRADIATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; ANTIBIOTIC PROPHYLAXIS; BLADDER TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; INTRAVESICAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MICROWAVE RADIATION; PROSPECTIVE STUDY; TUMOR RECURRENCE; UROLOGIC SURGERY;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MICROWAVES; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 0642368614     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.089     Document Type: Article

References (43)

1. Huland H, Otto U, Droese M, et al: Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence on recurrence, progression and survival. J Urol 132:27-29, 1984
2. Lamm DL, Riggs DR, Traynelis CL, et al: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444-1450, 1995
3. Lamm DL: Preventing progression and improving survival with BCG maintenance. Eur Urol 37:9-15, 2000 (suppl 1)
4. Lum BL, Torti FM: Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83:682-694, 1991
5. Solsona E, Iborra I, Dumont R, et al: The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685-689, 2000
6. Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: Progression and recurrence. J Urol 130:1083-1086, 1983
7. Smith G, Elton RA, Chisholm GD, et al: Superficial bladder cancer: Intravesical chemotherapy and tumour progression to muscle invasion or metastases. Br J Urol 58:659-663, 1986
8. Colombo R, Da Pozzo LF, Lev A, et al: Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155:1227-1232, 1996
9. Rigatti P, Lev A, Colombo R: Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors: A preliminary clinical study. Eur Urol 20:204-210, 1991
10. Colombo R, Lev A, Da Pozzo LF, et al: A new approach using local combined microwave-induced local hyperthermia in superficial transitional cell carcinoma treatment. J Urol 153:959-963, 1995
11. Colombo R, Da Pozzo LF, Lev A, et al: Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 159:783-787, 1998
12. Sylvester R: The analysis of results in prophylactic superficial bladder cancer studies, in: Schröder FH, Richards B (eds): EORTC Genitourinary Group Monograph 2: Part B-Superficial Bladder Tumors. New York, NY, Alan R Liss, 1985, pp 3-11
13. Hall RR, Wadehra V, Towler JM, et al: Hyperthermia in the treatment of bladder tumours. Br J Urol 48:603-608, 1976
14. Herman TS, Teicher BA, Jochelson M, et al: Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia 4:143-158, 1988
15. Ludgate CM, McLean N, Carswell GF, et al: Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma. Br J Urol 47:841-848, 1975
16. Newsam JE, Law HT: Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma: A review after 6 years. Br J Urol 54:64-65, 1982
17. Meyer JL: The clinical efficacy of localized hyperthermia: Cancer Res 44:4745s-4751s, 1984 (suppl 10)
18. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 39:2264-2268, 1979
19. Marmor JB: Interactions of hyperthermia and chemotherapy in animals. Cancer Res 39:2269-2276, 1979
20. Komatsu K, Miller RC, Hall EJ: The oncogenic potential of combination of hyperthermia and chemotherapy agents. Br J Cancer 57:59-63, 1988
21. Nakajima K, Hisazumi H: Enhanced radioinduced cytotoxicity of cultured human bladder cancer cells using 43 degrees C hyperthermia or anticancer drugs. Urol Res 15:255-260, 1987
22. Engelhardt R: Hyperthermia and drugs. Recent Results Cancer Res 104:136-203, 1987
23. Issell BF, Prout GR Jr, Soloway, et al: Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer 53:1025-1028, 1984
24. Krege S, Giani G, Meyer R, et al: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin: Participating Clinics. J Urol 156:962-966, 1996
25. Tolley DA, Parmar MK, Grigor Kaplan-Meier , et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up. J Urol 155:1233-1238, 1996
26. Hurle R, Manzetti A, Losa A, et al: Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: Long-term results. Urol Int 61:220-226, 1998
27. Nilsson S, Ragnhammar P, Glimelius B, et al: A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 40:371-390, 2001
28. Malmstrom PU, Wijkstrom H, Lundholm C, et al: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma: Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124-1127, 1999
29. Witjes JA, van der Meijden AP, Sylvester LC, et al: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacillus Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer: EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52:403-410, 1998
30. Kim HH, Chongwook L: Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol 141:1337-1340, 1989
31. Oosterlinck W, Lobel B, Jakse G, et al: Guidelines on bladder cancer: The commonly advocated doses for mitomycin C are 2-40 mg-European Association of Urology Guidelines. Arhem, the Netherlands, EAU Healthcare Office, 2001, p 9
32. Hetherington JW, Newling DW, Robinson MR, et al: Intravesical mitomycin C for the treatment of recurrent superficial bladder tumors. Br J Urol 59:239-241, 1987
33. Pavlotsky A, Eidelman A, Barak F, et al: Efficacy of intravesical mitomycin C in the treatment of superficial cell carcinoma of the urinary bladder. J Surg Oncol 41:9-11, 1989
34. Eijsten A, Knonagel H, Hotz E, et al: Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Br J Urol 66:386-388, 1990
35. Hobarth K, Maier U, Marberger M: Topical chemoprophylaxis of superficial cancer with mitomycin C and adjuvant hyluronidase. Eur Urol 21:206-210, 1992
36. Pavlotsky A, Eidelman A, Barak F, et al: Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C. J Surg Oncol 60:191-195, 1995
37. Otto T, Krege S, Noll F, et al: Therapy of superficial bladder carcinomas. Urol Int 63:32-39, 1999
38. Sakamoto N, Naito S, Kumazawa J, et al: Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumor following surgery for upper urinary tract tumors: A prospective randomised study. Int J Urol 8:212-216, 2001
39. Au JL, Badalament RA, Wientjes MG, et al: Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 93:597-604, 2001
40. Dalton JT, Wientjes MG, Badalament RA, et al: Pharmacokinetis of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144-5152, 1991
41. Wientjes MG, Badalament RA, Au JL: Use of pharmacologic data and computer simulations to design an efficacy trials of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 32:255-262, 1993
42. Gao X, Au JL, Badalament RA, et al: Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 4:139-143, 1998
43. Paroni R, Salonia A, Lev A, et al: Effect of local hyperthermia of the bladder on mytomicin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Pharmacol 52:273-278, 2001